Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer

This study has been completed.
Information provided by:
Roswell Park Cancer Institute Identifier:
First received: October 11, 2001
Last updated: March 3, 2011
Last verified: March 2011

RATIONALE: Photodynamic therapy uses light and drugs that make tumor cells more sensitive to light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells.

PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in treating patients who have non-small cell lung cancer.

Condition Intervention Phase
Lung Cancer
Drug: HPPH
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study

Resource links provided by NLM:

Further study details as provided by Roswell Park Cancer Institute:

Study Start Date: June 2001
Study Completion Date: October 2004
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the systemic and normal tissue toxicity of photodynamic therapy with HPPH in patients with early stage or centrally obstructing non-small cell lung cancer.
  • Determine, preliminarily, the efficacy of this regimen in these patients.

OUTLINE: This is a dose-escalation study of HPPH.

Patients receive HPPH IV over 1 hour on day 1. Patients undergo laser light therapy via bronchoscopy on day 3.

Cohorts of 3-6 patients receive escalating doses of HPPH until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed for at least 6 months.

PROJECTED ACCRUAL: Approximately 15-17 patients will be accrued for this study within 2 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed microinvasive or centrally obstructing non-small cell lung cancer

    • Squamous cell carcinoma
    • Adenocarcinoma
    • Large cell carcinoma



  • 18 and over

Performance status:

  • Karnofsky 50-100% OR
  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 2,000/mm^3
  • Platelet count at least 50,000/mm^3


  • Bilirubin no greater than 3.0 mg/dL
  • Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)
  • SGOT no greater than 3 times ULN
  • PT no greater than 1.5 times ULN


  • Creatinine no greater than 3.0 mg/dL


  • No severe chronic obstructive pulmonary disease that would preclude study


  • Not pregnant
  • Fertile patients must use effective contraception
  • No contraindications to bronchoscopy
  • No porphyria
  • No hypersensitivity to porphyrin or porphyrin-like compounds


Biologic therapy:

  • Prior biologic therapy for lung cancer allowed


  • At least 4 weeks since prior chemotherapy
  • No concurrent chemotherapy

Endocrine therapy:

  • Prior endocrine therapy for lung cancer allowed


  • At least 4 weeks since prior radiotherapy
  • No concurrent external beam radiotherapy


  • No concurrent surgery


  • Prior therapy for lung cancer allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00025571

United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
Study Chair: Gregory M. Loewen, DO, FCCP Roswell Park Cancer Institute
  More Information

Responsible Party: Gregory Loewen, MD, Roswell Park Cancer Institute Identifier: NCT00025571     History of Changes
Other Study ID Numbers: CDR0000068974
Study First Received: October 11, 2001
Last Updated: March 3, 2011

Keywords provided by Roswell Park Cancer Institute:
squamous cell lung cancer
large cell lung cancer
adenocarcinoma of the lung
stage I non-small cell lung cancer
stage II non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on May 24, 2017